Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Genre:||Health and Food|
|Published (Last):||16 September 2007|
|PDF File Size:||11.30 Mb|
|ePub File Size:||6.12 Mb|
|Price:||Free* [*Free Regsitration Required]|
Requires a specialized care setting, requires an experienced clinician.
There was a problem providing the content you requested
Total clearance of dofetilide is decreased and plasma concentration is increased in proportion to the decline in creatinine clearance associated with renal disease. Severe Treatment with clozapine has been associated with Packahe prolongation, torsade de pointes TdPcardiac arrest, and sudden death. Vandetanib can prolong the QT interval in a concentration-dependent manner. No dosage adjustment is needed for patients with mild to moderate hepatic impairment. Severe The concurrent use of amiodarone and dofetilide is contraindicated.
Because of the potential for TdP, use of dofetilide with triptorelin is contraindicated.
Dofetilide, a Class III antiarrhythmic, is proarrhythmic and may induce or worsen cardiac arrhythmias. Before administering macimorelin, pckage use of dofetilide and allow a sufficient washout period to pass. Severe There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval.
Severe Terfenadine has an established association with QT prolongation and torsade de pointes tdP. The maximal change in the QTc interval occurs approximately 5 to 10 hours following doofetilide administration of gemifloxacin. Severe Coadministration of dofetilide and eliglustat is contraindicated.
If the QTc exceeds milliseconds or msec in patients with ventricular conduction abnormalities at any time, dofetilide therapy should be discontinued. Because of the potential for torsade de pointes TdPuse of dofetilide with olanzapine is contraindicated.
Severe Eribulin has been associated with QT prolongation. John’s Wort, Hypericum perforatum: Major It would be prudent to avoid use of Hawthorn, Crataegus laevigata also known as C.
Dofetilide (Tikosyn) | Pharmacy
Because of the potential for TdP, use of dofetilide with norfloxacin is contraindicated. To minimize the risk of proarrhythmias, patients initiated or re-initiated on dofetilide should be placed for 3 or more days cofetilide a monitored facility with the capacity to monitor continuous ECG and CrCl and perform cardiac resuscitation. Severe Ezogabine has been associated with QT prolongation.
Because of the potential for TdP, dofetilide is contraindicated with any drugs associated with QT prolongation. Moderate Drugs that are actively secreted via cationic secretion, such as lamivudine, should be co-administered with dofetilide with caution since they could increase dofetilide plasma concentrations via potential competition for renal tubular secretion.
Because of the potential for TdP, use of dofetilide with fluconazole is contraindicated. Because of the potential for TdP, coadministration is contraindicated.
Because of the potential for TdP, concurrent use is contraindicated. Vemurafenib has been associated with QT prolongation. Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses.
John’s wort could decrease the efficacy of some medications metabolized by CYP3A4, such as dofetilide.
According to the manufacturer, Packagr I disopyramide, encainide, flecainide, lidocaine, mexiletine, moricizine, procainamide, propafenone, quinidine, and tocainide antiarrhythmic agents are associated with QT prolongation and ventricular arrhythmias and packafe exposure with dofetilide could increase the risk of dofetilide-induced proarrhythmias.
Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with rucaparib is necessary. Anticoagulant therapy may be continued after cardioversion for the treatment of patients with atrial fibrillation. Severe Because of the potential for torsade de pointes TdPuse of toremifene with dofetilide is contraindicated.
Dofetilide – GlobalRPH
Because of the potential for TdP, use of halogenated anesthetics with dofetilide is contraindicated. Solifenacin has been associated dose-dependent prolongation of the QT interval. Administration of dofetilide requires a specialized dofwtilide setting; treatment with dofetilide may be packagw only in patients placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic ECG monitoring, and cardiac resuscitation. Severe Cimetidine is an inhibitor of renal cationic tubular secretion and is contraindicated with dofetilide due to the potential for increased plasma dofetilide concentrations and associated proarrhythmias.
Severe Coadministration of gemtuzumab ozogamicin with dofetilide is contraindicated due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP. However, the incidence of ventricular arrhythmias other than TdP pckage similar in female patients receiving dofetilide and patients receiving placebo. Because of the potential for TdP, use of dofetilide with risperidone is contraindicated. In patients who are also receiving treatment with cyclosporine, the magnitude of this interaction may be amplified.
Dofetilide is administered orally. Severe Pazopanib has been reported to prolong the QT interval.